The Week in Review: April 6 – April 13, 2018

Friday, April 13, 2018 News Recap: Canada: Initiative aims to treat Hepatitis C in Alberta patients who also have HIV. A long-term effort to eliminate Hepatitis C as a public health threat is underway in Alberta, where a new program aims to provide medications to one particularly vulnerable group of patients. NOTE: In Alberta, coverage has been expanded as of April 1 to include all patients with hepatitis C. Previously, coverage was provided only to...

Non-profit’s $300 hepatitis C cure as effective as $84,000 alternative

71 million people stand to benefit from reduced price treatment for virus which can lead to liver cirrhosis, cancer and death. An affordable hepatitis C treatment has been shown to be safe and effective, with very high cure rates for patients including hard-to-treat cases, in interim clinical trial results that offer hope to the 71 million people living with the disease worldwide. The treatment is expected to cost $300 for 12 weeks, or $3.50 per day, i...

The Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate Ravidasvir

AMSTERDAM, April 21, 2017 /PRNewswire/ -- Agreement seeks to improve health options for hepatitis C patients in low- and middle-income countries The Medicines Patent Pool (MPP) announced a new licence and technology transfer agreement with Egyptian company Pharco Pharmaceuticals for ravidasvir (RAV), an investigational direct-acting antiviral (DAA) with the potential of working across all six major hepatitis C genotypes. The agreement, signed on the sidel

Doctors Without Borders urges Gilead to rethink its hepatitis C strategy in Ukraine

The latest battle over access to medicines is taking place in Ukraine, where Doctors Without Borders is urging Gilead Sciences to drop a court action that, if successful, would prevent a generic version of the Sovaldi hepatitis C treatment from remaining available. In a Sept. 5 letter released publicly Tuesday, Gilead was asked to “reconsider its business strategy in high-burden, middle-income countries, especially Ukraine,” since its strategies “threaten